

## **Chemotherapy, Epidemiology, Diagnosis, Management, and Treatment of Breast Cancer**

**RA. Tjitra Chairulita<sup>1</sup>**

<sup>1</sup> Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur

### **Corresponding Author**

RA. Tjitra Chairulita

Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur

Jalan Rungkut Madya No. 191, Rungkut Kidul, Rungkut Subdistrict, Surabaya, East Java 60293

Tel/Fax: +628885155352

E-mail: racitrachairulita@gmail.com

### **ABSTRACT**

Asthma is a chronic inflammatory disease of the airways triggered by an immune response involving Th22 cells and group 3 innate lymphoid cells (ILC2). The disease is divided into two main endotypes: type 2-high, characterized by eosinophilic inflammation and a good response to corticosteroids; and type 2-low, which is associated with neutrophilic inflammation and a response to non-type 2 cytokines. The aim of this literature review is to examine the immunology of asthma, its pathogenesis, biomarkers, genetics, epigenetics, and management strategies. Literature was sourced from several databases such as Google Scholar and PubMed using relevant keywords. The review findings indicate that type 2-high asthma responds well to corticosteroid therapy, whereas type 2-low asthma requires treatment targeting non-type 2 cytokines. Biomarker-based approaches are crucial in asthma management, with studies showing that plant-based diets and vitamin D intake can help control asthma. A deeper understanding of asthma endotypes and associated biomarkers is essential for developing more personalized and effective treatment strategies.

**Keyword :** Asthma; biomarkers; endotype; immunology

### **Introduction**

Breast cancer is a global health concern and remains one of the leading causes of cancer-related deaths among women. Over the past few decades, there has been significant progress in the understanding of the epidemiology, diagnosis, and treatment of breast

cancer<sup>1</sup>. However, challenges in the management of this disease persist, especially regarding chemotherapy resistance, late diagnosis, and the growing incidence of breast cancer in certain populations. Early detection and effective treatment remain critical in improving the survival rates and quality of life for breast cancer patients worldwide.

The global burden of breast cancer varies across different regions, with distinct epidemiological patterns observed between Western and Asian countries. In Western countries, such as the United States and parts of Europe, breast cancer is more common among older women, with an increased incidence after the age of 50. In contrast, in Asian countries, although the overall incidence of breast cancer is lower, there has been a notable rise in cases among younger women in recent years<sup>2</sup>. This shift in the epidemiology of breast cancer in Asia presents a unique challenge for healthcare providers, as younger women are often diagnosed at more advanced stages of the disease due to the lack of widespread screening programs and the less frequent occurrence of symptoms in early stages.

Chemotherapy has long been a cornerstone of treatment for breast cancer, particularly in cases of advanced-stage or metastatic disease. However, the development of resistance to chemotherapy drugs remains one of the most significant obstacles in achieving effective long-term outcomes. Chemotherapy resistance occurs when cancer cells adapt to the drugs intended to kill them, making treatment less effective or entirely ineffective. This phenomenon has been a central focus of recent research, which aims to understand the underlying mechanisms of resistance and develop strategies to overcome it. In addition to chemotherapy resistance, managing side effects remains an essential component of treatment, as the adverse effects of chemotherapy can significantly impact patients' quality of life and their ability to continue with treatment<sup>3</sup>.

The importance of early detection in breast cancer cannot be overstated. Early diagnosis significantly improves the chances of successful treatment and long-term survival. Mammography remains the most widely used method for breast cancer screening, but its effectiveness can be limited by factors such as breast density and age. Moreover, while advances in imaging techniques and biomarkers have improved early detection, challenges in achieving timely and accurate diagnoses persist, particularly in resource-limited settings<sup>4</sup>. As a result, there is a growing emphasis on developing more accessible and effective diagnostic methods that can aid in the early detection of breast cancer, particularly in low- and middle-income countries where access to healthcare may be limited.

The development of targeted therapies has provided new hope for breast cancer

patients, especially those with specific molecular subtypes of the disease. One such therapy is abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which has shown promise in improving progression-free survival in patients with hormone receptor-positive, HER2-negative breast cancer<sup>5</sup>. This class of drugs works by inhibiting the proteins that drive the uncontrolled growth of cancer cells, offering a more targeted approach to treatment that reduces damage to healthy cells. The effectiveness of abemaciclib and similar therapies represents a significant advancement in the treatment of breast cancer, providing patients with more treatment options and improving their chances of achieving remission<sup>6</sup>.

Given the complex and multifaceted nature of breast cancer, this research aims to explore the latest developments in the epidemiology, diagnosis, chemotherapy, and management of the disease. By focusing on recent advancements in treatment and diagnostic methods, the study seeks to contribute to the growing body of knowledge that will ultimately improve the care and outcomes for breast cancer patients. This research will also address the ongoing challenges in overcoming chemotherapy resistance and developing more effective therapies for patients at high risk of recurrence or metastasis. Through this comprehensive approach, the study aims to inform healthcare providers and researchers working toward better strategies for breast cancer prevention, detection, and treatment, ultimately improving survival rates and quality of life for women worldwide.

## **Material and Methods**

This study employs a literature review methodology to explore the chemotherapy, epidemiology, diagnosis, management, and treatment of breast cancer. A systematic review of recent scholarly articles, clinical studies, and research papers was conducted using reputable academic databases, such as PubMed, Elsevier, Google Scholar, and ScienceDirect, with a focus on publications from 2019 to 2022. The inclusion criteria for selecting articles were based on relevance to the research objectives, ensuring that the sources addressed key aspects of breast cancer, including its epidemiology, diagnostic methods, chemotherapy treatments, and the latest advancements in targeted therapies. The review includes peer-reviewed journals, clinical trials, and meta-analyses that discuss chemotherapy resistance, the rise in incidence of breast cancer, and the efficacy of emerging therapies like abemaciclib. Through this approach, the study aims to compile the most up-to-date and comprehensive information regarding breast cancer treatment and diagnosis, providing insights into current trends, challenges, and potential areas for future research.

## **Discussion**

### **Chemoresistance and Stemness in Breast Cancer Cells**

The study by Yang et al. provides significant insights into the role of chemotherapy-elicited exosomal microRNAs in promoting breast cancer stemness and chemoresistance. Their research reveals that chemotherapy induces the release of exosomes containing miR-378a-3p and miR-378d, which activate signaling pathways such as EZH2/STAT3. This activation leads to increased stemness and chemoresistance in neighboring cancer cells <sup>7</sup>. The findings emphasize the adaptive mechanisms of breast cancer cells in response to chemotherapy, showing that microRNAs within exosomes can enhance the cancerous phenotype by targeting key proteins like DKK3 and NUMB. This mechanism presents potential therapeutic avenues, such as the combination of chemotherapy with EZH2 inhibitors to combat chemoresistance and improve treatment outcomes.

The study highlights the importance of these exosomal microRNAs in enhancing the cancerous phenotype. By targeting key proteins like DKK3 and NUMB, the microRNAs contribute to the aggressive nature of breast cancer cells, allowing them to survive chemotherapy and continue to proliferate <sup>8</sup>. The findings emphasize that these adaptive mechanisms are part of the cancer cells' survival strategy against chemotherapy. This research also opens up promising avenues for future therapeutic strategies, particularly through the combination of chemotherapy with EZH2 inhibitors. Such combined treatments could help in overcoming chemoresistance, potentially improving the effectiveness of breast cancer therapies and patient outcomes.

### **Epidemiology and Pathological Differences between Asian and U.S. Populations**

Lin et al. conducted a comparative study on the epidemiology and clinicopathology of breast cancer between Asian and U.S. populations, revealing significant differences in both incidence rates and cancer characteristics. Notably, the study observed a rising incidence of breast cancer in younger women in Asia, particularly those under 50 years old, with a high prevalence of estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) cancers <sup>9</sup>. In contrast, women in the U.S. tend to experience breast cancer at older ages, particularly after 60. This epidemiological shift highlights the potential impact of genetic, environmental, and lifestyle factors on breast cancer risk in different populations. The findings suggest the need for tailored prevention and treatment strategies for Asian populations, particularly as they face increasing rates of breast cancer at younger ages.

The study found that women in the U.S. tend to develop breast cancer at older ages,

particularly after the age of 60. This significant difference in age of onset between the two populations underscores the impact of genetics, lifestyle, and environmental exposures on breast cancer risk. The findings of this study suggest that the risk factors for breast cancer may vary between populations, and this could influence both the prevention and treatment strategies. With the rising incidence of breast cancer among younger women in Asia, there is an urgent need to develop more tailored strategies for early detection, prevention, and treatment, which may differ from the strategies applied in Western countries where the incidence is higher in older populations <sup>10</sup>.

#### Advancements in Breast Cancer Diagnosis using Artificial Intelligence

Muduli et al. contributed to the advancement of breast cancer diagnosis by utilizing deep convolutional neural networks (CNN) for automated analysis of mammogram and ultrasound images. Their study demonstrated that CNN-based models can classify images with remarkable accuracy, outperforming traditional methods. For example, the model achieved accuracy rates of 96.55% for mammograms in the MIAS dataset and 100% for ultrasound in the BUS-1 dataset. These results underscore the potential of AI-driven systems in improving the speed and effectiveness of breast cancer detection, offering an efficient and reliable alternative to manual image interpretation. This technological approach could significantly reduce diagnostic errors and expedite early detection, ultimately improving patient outcomes <sup>11</sup>.

#### Conclusion

The findings from the studies summarized in this table reveal various factors influencing the development and management of breast cancer, encompassing biological, epidemiological, and therapeutic aspects. One study highlighted the role of exosomes produced by breast cancer cells in enhancing stemness and chemoresistance through the EZH2/STAT3 signaling pathway. Another study found significant differences in the epidemiology of breast cancer between Asian women and those in the U.S., noting an increase in incidence among younger Asian women. Additionally, advancements in breast cancer diagnosis were observed through technologies like CNN models, which demonstrated high accuracy in classifying mammograms and ultrasounds. Clinical studies also emphasized the importance of managing drug side effects in breast cancer therapy, such as with abemaciclib, which showed an acceptable safety profile. Overall, these studies provide valuable insights into the biological mechanisms of breast cancer, challenges in diagnosis, and therapeutic developments that could improve treatment outcomes and the quality of life

for breast cancer patients.

## References

1. Yang Q, Zhao S, Shi Z, Cao L, Liu J, Pan T, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. *J Exp Clin Cancer Res.* 2021;40:1-18.
2. Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. *JNCI Cancer Spectrum.* 2019;111(12):1298-1306.
3. Muduli D, Dash R, Majhi B. Automated diagnosis of breast cancer using multimodal datasets: A deep convolution neural network-based approach. *Biomed Signal Process Control.* 2022;71:102825.
4. Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Safety analysis of MONARCH 2 and MONARCH 3. *Oncologist.* 2021;26(1):e53-e65.
5. Johnston SR, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). *J Clin Oncol.* 2020;38(34):3987-3998.
6. Conte L, Lupo R, Sciolti S, Lezzi A, Rubbi I, Botti S, et al. Exploring the landscape of breast cancer prevention among Chinese residents in Italy: An in-depth analysis of screening adherence, breast self-examination (BSE) practices, the role of technological tools, and misconceptions surrounding risk factors and symptoms. *Int J Environ Res Public Health.* 2024;21(3):1-26. doi: 10.3390/ijerph21030308.
7. Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, Behnam B. Overcoming chemotherapy resistance in metastatic cancer: A comprehensive review. *Biomedicines.* 2024;12(1):1-28. doi: 10.3390/biomedicines12010183.
8. Li Q, He G, Yu Y, Li X, Peng X, Yang L. Exosome crosstalk between cancer stem cells and tumor microenvironment: Cancer progression and therapeutic strategies. *Stem Cell Res Ther.* 2024;15(1):449. doi: 10.1186/s13287-024-04061-z.
9. Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast cancer—Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. *Cancers.* 2021;13:4287.
10. Luana Conte et al., “Exploring the Landscape of Breast Cancer Prevention among Chinese

Residents in Italy: An In-Depth Analysis of Screening Adherence, Breast Self-Examination (BSE) Practices, the Role of Technological Tools, and Misconceptions Surrounding Risk Factors and Symptoms,” *International Journal of Environmental Research and Public Health* 21, no. 3 (2024): 1–26, <https://doi.org/10.3390/ijerph21030308>.

11. Muduli, D., Dash, R., & Majhi, B. (2022). Automated diagnosis of breast cancer using multimodal datasets: A deep convolution neural network-based approach. *Biomedical Signal Processing and Control*, 71, 102825.